Table 1 Demographic, clinical characteristics and laboratory findings of SFTS patients
Characteristics | SFTS (n = 6) |
|---|---|
Epidemiology, no. (%) | |
 Age, mean Y ± SD (range) | 74.33 ± 10.97 |
 Female | 4 (66.7) |
 Occupational exposure | 2 (33.3) |
Comorbidities, no. (%) | |
 Cardiovascular diseasea | 0 |
 Cerebrovascular disease | 0 |
 Pulmonary diseaseb | 0 |
 Chronic kidney disease | 0 |
 Diabetes mellitus | 1 (16.7) |
 Malignancies | 0 |
Clinical signs and symptoms, no. (%) | |
 Headache | 2 (33.3) |
 Dyspepsia | 3 (50.0) |
 Nausea/vomiting | 3 (50.0) |
 Abdominal pain | 3 (50.0) |
 Chills | 5 (83.3) |
Myalgia | 5 (83.3) |
 Fatigue | 5 (83.3) |
 Rash/eschar | 3 (50.0) |
 Tick bite | 3 (50.0) |
Laboratory values, median (IQR) | |
 WBC count, ×1000/mm3 | 1.6 (1.2–2.4) |
 Platelet count, ×1000/mm3 | 100.0 (51.0–118.0) |
 aPTT, sec | 34.7 (27.8–44.0) |
 Total bilirubin, mg/dL | 0.35 (0.25–0.95) |
 Albumin, g/dL | 4.0 (3.6–4.7) |
 AST, IU/L | 148.5 (26.0–727.0) |
 ALT, IU/L | 104.0 (15.0–190.0) |
 LD, IU/L | 673.5 (421.0–1914.0) |
 Creatinine, mg/dL | 0.7 (0.5–1.3) |
 hs-CRP, mg/dL | 4.5 (0.2–13.7) |
Clinical outcomes | |
 Length of hospital stay, median (IQR) | 9 (7.0–18.0) |
 In-hospital mortality, no. (%) | 2 (33.3) |